Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Coffee Silverskin Extract: Nutritional Value, Safety and Effect on Key Biological Functions.

Iriondo-DeHond A, Rios MB, Herrera T, Rodriguez-Bertos A, Nuñez F, San Andres MI, Sanchez-Fortun S, Del Castillo MD.

Nutrients. 2019 Nov 7;11(11). pii: E2693. doi: 10.3390/nu11112693.

2.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE.

Int J Hematol. 2019 May;109(5):545-552. doi: 10.1007/s12185-019-02620-2. Epub 2019 Mar 4.

PMID:
30830579
3.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J.

J Hematol Oncol. 2019 Jan 3;12(1):1. doi: 10.1186/s13045-018-0686-1.

4.

Geographic range expansion of Ephippion guttifer (Tetraodontidae) in the north-eastern Atlantic.

Bañón R, Alonso-Fernández A, Barros-García D, Rios MB, de Carlos A.

J Fish Biol. 2018 Oct;93(4):733-737. doi: 10.1111/jfb.13761.

PMID:
30051566
5.

Quantitative Thresholds Enable Accurate Identification of Clostridium difficile Infection by the Luminex xTAG Gastrointestinal Pathogen Panel.

Leal SM Jr, Popowitch EB, Levinson KJ, John TM, Lehman B, Rios MB, Gilligan PH, Miller MB.

J Clin Microbiol. 2018 May 25;56(6). pii: e01885-17. doi: 10.1128/JCM.01885-17. Print 2018 Jun.

6.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.

Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H.

Int J Hematol. 2018 Jun;107(6):689-695. doi: 10.1007/s12185-018-2422-6. Epub 2018 Feb 20.

PMID:
29464484
7.

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.

Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE.

Cancer. 2018 Mar 15;124(6):1160-1168. doi: 10.1002/cncr.31187. Epub 2017 Dec 20.

8.

A sexually dimorphic pre-stressed translational signature in CA3 pyramidal neurons of BDNF Val66Met mice.

Marrocco J, Petty GH, Ríos MB, Gray JD, Kogan JF, Waters EM, Schmidt EF, Lee FS, McEwen BS.

Nat Commun. 2017 Oct 9;8(1):808. doi: 10.1038/s41467-017-01014-4.

9.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE.

Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23.

10.

Fibroblast growth factor 2 alters the oxytocin receptor in a developmental model of anxiety-like behavior in male rat pups.

Litvin Y, Turner CA, Rios MB, Maras PM, Chaudhury S, Baker MR, Blandino P Jr, Watson SJ Jr, Akil H, McEwen B.

Horm Behav. 2016 Nov;86:64-70. doi: 10.1016/j.yhbeh.2016.09.009. Epub 2016 Sep 28.

11.

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.

Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE.

Haematologica. 2016 Aug;101(8):e324-7. doi: 10.3324/haematol.2015.139089. Epub 2016 May 12. No abstract available.

12.

Activity-based anorexia during adolescence disrupts normal development of the CA1 pyramidal cells in the ventral hippocampus of female rats.

Chowdhury TG, Ríos MB, Chan TE, Cassataro DS, Barbarich-Marsteller NC, Aoki C.

Hippocampus. 2014 Dec;24(12):1421-9. doi: 10.1002/hipo.22320. Epub 2014 Jul 18.

13.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.

Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J.

Leuk Lymphoma. 2014 Dec;55(12):2879-86. doi: 10.3109/10428194.2013.831092. Epub 2013 Sep 10.

14.

Episodic-like memory: new perspectives from a behavioral test in rats.

Weisz VI, Rios MB, Argibay PF.

J Integr Neurosci. 2012 Mar;11(1):1-15.

PMID:
22744780
15.

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):197-200. doi: 10.1016/j.clml.2012.03.004.

16.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S.

Lancet Oncol. 2012 Apr;13(4):403-11. doi: 10.1016/S1470-2045(11)70386-2. Epub 2012 Feb 21.

PMID:
22357140
17.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J.

Blood. 2012 Mar 1;119(9):1981-7. doi: 10.1182/blood-2011-08-358135. Epub 2012 Jan 6.

18.

Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

Rios MB, Ault P.

Clin J Oncol Nurs. 2011 Dec;15(6):660-7. doi: 10.1188/11.CJON.660-667.

PMID:
22119977
19.

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE.

J Clin Oncol. 2011 Nov 10;29(32):4260-5. doi: 10.1200/JCO.2011.36.0693. Epub 2011 Oct 11.

20.

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J.

Blood. 2011 Oct 20;118(16):4353-8. doi: 10.1182/blood-2011-06-362889. Epub 2011 Aug 16.

21.

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J.

Blood. 2011 Oct 27;118(17):4541-6; quiz 4759. doi: 10.1182/blood-2011-04-348110. Epub 2011 Jul 29.

22.

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J.

Blood. 2011 Feb 10;117(6):1822-7. doi: 10.1182/blood-2010-07-293977. Epub 2010 Oct 28.

23.

Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.

Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J.

Blood. 2010 Jul 1;115(26):5428-9. doi: 10.1182/blood-2009-11-252155. No abstract available.

PMID:
20595523
24.

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.

Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J.

Cancer. 2010 Jul 1;116(13):3152-9. doi: 10.1002/cncr.25071.

25.

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

Abdel-Karim I, Plunkett WK Jr, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM.

Invest New Drugs. 2011 Apr;29(2):323-31. doi: 10.1007/s10637-009-9369-7. Epub 2010 Jan 21.

26.

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J.

Blood. 2009 Sep 10;114(11):2232-5. doi: 10.1182/blood-2009-02-204693. Epub 2009 Jun 16.

27.

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.

Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J.

J Clin Oncol. 2009 Aug 1;27(22):3659-63. doi: 10.1200/JCO.2008.18.6999. Epub 2009 Jun 1.

28.

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J.

Blood. 2009 May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12.

29.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J.

Blood. 2009 Mar 5;113(10):2154-60. doi: 10.1182/blood-2008-04-154344. Epub 2008 Dec 5.

30.

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.

Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.

Mol Cancer Ther. 2008 Jan;7(1):48-58. doi: 10.1158/1535-7163.MCT-07-0042.

31.

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.

Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H.

Blood. 2007 Nov 15;110(10):3547-51. Epub 2007 Aug 2.

PMID:
17673605
32.

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J.

Blood. 2007 Oct 15;110(8):2991-5. Epub 2007 Jul 11.

PMID:
17625066
33.

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H.

Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S51-7. Review.

PMID:
17382013
34.

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.

Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J.

Cancer. 2007 Apr 15;109(8):1556-60.

35.

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J.

Leukemia. 2006 Oct;20(10):1767-73. Epub 2006 Jul 20.

PMID:
16855631
36.

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.

Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18.

PMID:
16709931
37.

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.

Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM.

Cancer. 2006 Mar 15;106(6):1306-15.

38.

Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J.

J Clin Oncol. 2006 Mar 1;24(7):1204-8. Epub 2006 Jan 30.

PMID:
16446320
39.

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J.

Blood. 2006 Jan 15;107(2):480-2. Epub 2005 Sep 29.

PMID:
16195326
40.

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J.

Leuk Lymphoma. 2005 Jul;46(7):993-7.

PMID:
16019549
41.

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J.

Cancer. 2005 Aug 15;104(4):777-80.

42.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

43.

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.

Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J.

Cancer. 2005 May 15;103(10):2099-108.

44.

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J.

Blood. 2005 Mar 15;105(6):2281-6. Epub 2004 Nov 30.

PMID:
15572595
45.

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H.

Cancer. 2004 Jul 15;101(2):332-6.

46.

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M.

Blood. 2004 Oct 1;104(7):1979-88. Epub 2004 Jun 15.

PMID:
15198956
47.

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.

Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J.

Cancer. 2004 Jun 15;100(12):2592-7.

48.

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.

Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M, Kantarjian H.

Cancer. 2004 Jun 1;100(11):2396-402.

49.

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.

Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J.

Leuk Res. 2004 Jun;28(6):613-8.

PMID:
15120938
50.

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.

Blood. 2004 Apr 15;103(8):2873-8. Epub 2003 Dec 24.

PMID:
15070658

Supplemental Content

Support Center